A randomized, double-blinded, single-center, placebo-controlled phase I clinical trial of XVR011 in healthy subjects
Latest Information Update: 23 Aug 2021
At a glance
- Drugs XVR 011 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- 23 Aug 2021 New trial record
- 18 Aug 2021 According to an ExeVir Bio media release, first subject has been dosed in the trial.